NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000002453

Registered date:01/04/2010

2nd-line Tarceva+ALIMTA for EGFR mutation negative non-small, non-squamous lung cancer (TALIMTA STUDY)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiednon-sq NSCLC
Date of first enrollment2009/10/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)chemotherapy with erlotinib and pemetrexed

Outcome(s)

Primary Outcomedisease control rate
Secondary Outcomeoverall survival, progression-free survival, 1-year survival, safety

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1)previous chemotherapy with erlotinib, gefitinib, or pemetrexed 2)interstitial pneumoia/active lung fibrosis on chest x-ray 3)massive or uncontrolable pleural effusion 4)symptomatic brain metastasis 5)active concomitant malignancy 6)severe comorbidity 7)pregnant or lactating woman 8)history of severe drug allergy 9)psychiatry disease

Related Information

Contact

public contact
Name
Address Japan
Telephone
E-mail
Affiliation Kyoto University Hospital Respiratory Medicine
scientific contact
Name Young Hak Kim
Address 54 Shogoin-Kawaharacho Sakyo-ku Kyoto Japan
Telephone
E-mail
Affiliation Kyoto University Hospital Respiratory Medicine